Lutronic Changes the Game with the Derma V Dermatology Platform

Lutronic, the global leader in intelligent, energy-based systems for medical aesthetics, introduces Derma V, a ground-breaking dermatology workstation. Combining three unique treatment approaches – the core of a dermatologist’s toolbox – in one single, precise, powerful machine. Derma V has completely redefined the dermatology workstation. After years in the making, Lutronic has set an exceptional new standard for innovation and excellence with Derma V.

“We created a device that brings the essential lasers that skin specialists need for their daily work – vascular, pigment and rejuvenation – into a single, powerful and user-friendly technology,” states James Bartholomeusz, Lutronic’s Chief Technology Officer. “Lutronic improved every aspect of currently available platforms: usability, speed, safety, and tracking technology. This is the kind of leap in technological innovation that only happens every 15-20 years.”

Prior to Derma V, dermatologists and skin specialists were forced to juggle technologies, switching from one purpose-built laser to another to use the right tool for the right procedure, often sacrificing efficacy and safety for speed and useability, or vice-versa. A pulsed dye laser has long been the laser of choice for addressing various vascular issues but doesn’t target pigment concerns. While this laser may be safest and currently most efficacious, there are drawbacks to using it in a busy practice, such as breakdown-prone components and replaceable dyes that are less than ideal. This technology, in use across the industry, was long overdue for a complete reimagining.

Combining gold standard ICD skin cooling, optimal fluence, optimal wavelengths and flexible pulse duration and structures, the Derma V redefines what a 532nm “green” laser can be. The Derma V has over three times more power than the next best green laser, resulting in a wider range of fluence and spot size that help its more flexible wavelength penetrate deeper. It dramatically increases the range of possible treatments compared to green lasers of the past. Optimal cryogen based epidermal protection allows the operator to treat with the energy and power required for tough vascular lesions and to work quickly and efficiently, while providing comfort without pressure sensitivity or contact gels.

IntelliTrack™, Derma V’s proprietary, contact-based speed sensing technology, automatically tracks movement of the handpiece, delivering perfect coverage of the treatment area 3 times faster than any other solutions.

Dermatologists currently testing Derma V are enthusiastic. “I can precisely select the pulse wavelength and structure,” says Dr. Suzanne Kilmer, of Sacramento, CA. “Whether I’m targeting melanin, scars, or vessels of any size, I can pick and choose my ideal parameters. I’m effectively treating vascular lesions, as well as port wine stains that had not been responding as well to other laser treatments. I’m achieving safe and effective results with no side effects, and I can treat a large area much faster than I could with my old lasers.”

“Dermatologists need their technology – which they use all day, every day – to be as fast and reliable. They want multiple wavelengths and more power to be able to treat the widest array of pigment, vascular conditions,” Bartholomeusz explains. “But they also care about safety and keeping their patients comfortable. With Derma V, we created a workstation that brings the 532nm green laser together with the most powerful 1064nm laser to cover all the current treatment needs. These things, plus ICD cooling and IntelliTrack™, differentiate Lutronic’s state-of-the-art Derma V dermatology workstation from the rest, and set a new global standard for platform laser technology.”


Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy